RecruitingNot ApplicableNCT03747133

SABR for Renal Tumors

Phase II Study: Stereotactic Ablative Radiotherapy for Renal Tumors

Sponsor

University Health Network, Toronto

Enrollment

45 participants

Start Date

Nov 1, 2018

Study Type

INTERVENTIONAL

Conditions

Renal Tumor

Summary

Renal Cell Carcinoma (RCC) is the most common type of kidney cancer. The usual treatment for this type of cancer is surgery. Considering the most common patients are an average age of 65 and some are not suitable candiates for surgery, there is great interest in non-surgical alternatives for kidney cancer treatments. This study will investigate the use of Stereotactic Ablative Radiosurgery (SABR) for renal tumors. SABR is a non-invasive alternative, which involves delivery of high doses of radiation to the target, while minimizing the risk of injury to the surrounding organs. Patients will be seen before and end of treatmetn and will be followed at 4 month intervals for up to 2 years. During the follow ups, patients will be asked to complete a quality of life questionnaire and will have standard of care imaging.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This trial is studying a type of precise, high-dose radiation called SABR (Stereotactic Ablative Body Radiotherapy) as a treatment for kidney tumors in people who are either too high-risk for surgery or have chosen not to have surgery. **You may be eligible if...** - You have a solid kidney tumor (primary kidney cancer or a spread from another cancer) that is 6 cm or smaller - Your tumor has been confirmed by imaging or biopsy - You are not a good candidate for surgery or have declined surgery - Your general health allows for outpatient radiation treatment (ECOG performance status 0–3) **You may NOT be eligible if...** - You have 5 or more active cancer sites elsewhere in your body - You have received systemic cancer therapy (other than hormonal drugs) within 6 days before the radiation - You have had prior abdominal radiation that would overlap with this treatment - You have end-stage kidney failure Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.